Featured content in this Issue: Companies, organisations and drug candidates mentioned in this Bulletin: EQUULUS Therapeutics; EQL-101; EQL-201; Gilgamesh Pharmaceuticals; DemeRx; atai Life Sciences; Delix Therapeutics; CaaMTech; Lykos Therapeutics; Beckley Psytech; BPL-003; Compass Pathways; Clairvoyant Therapeutics. This is the first issue of our Psychedelic Bulletin that’s exclusively…

Source

Previous articleDecolonization, Difficult Conversations, and the Challenge of Merging Spirituality and Science
Next articleThe Ketamine Conundrum
admin
https://psynews.com

RELATED ARTICLESMORE FROM AUTHOR